Posts

Posted on

AlphaTON Capital Deploys First H200 GPUs on Cocoon AI Network, Launches Revolutionary #OwnYourNode Program to Democratize AI Infrastructure Ownership

Partnership with Atlantian Cybernetics Development Cluster (AC|DC) Enables Retail and Institutional Access to Fractionalized GPU Ownership in Telegram’s Decentralized AI Ecosystem

ABU DHABI, UNITED ARAB EMIRATES, Dec. 08, 2025 (GLOBE NEWSWIRE) — AlphaTON Capital Corp (NASDAQ: ATON), the world’s leading public technology company scaling the Telegram super app, with an addressable market of 1 billion monthly active users, today announced the successful deployment and activation of its first NVIDIA H200 GPUs on Telegram’s Cocoon AI Network. The H200s are now online and actively generating revenue, marking a significant milestone in the company’s strategy to provide critical infrastructure for decentralized AI computing.

In conjunction with this deployment, AlphaTON Capital is launching a groundbreaking program in partnership with Atlantian Cybernetics Development Cluster (AC|DC) to democratize access to AI infrastructure ownership. The #OwnYourNode initiative will enable individuals and institutions to purchase fractionalized GPUs, whole GPUs, and mini clusters, allowing unprecedented participation in supporting and profiting from the growth of Telegram’s Cocoon AI network.

“The deployment of our first H200s alongside the #OwnYourNode program represents more than just hardware going online, it’s the beginning of a fundamental shift in how AI infrastructure is owned and operated,” said Brittany Kaiser, CEO of AlphaTON Capital. “With the #OwnYourNode program, we’re breaking down the barriers that have traditionally kept everyday people out of the AI infrastructure market. Now anyone can own a piece of the decentralized AI revolution powering Telegram’s ecosystem and participate in both the economic value and ethical, privacy-centric, tech stack created by these powerful computing resources.”

The H200 GPUs, in addition to the B200s AlphaTON announced deployment of last week, represent some of the most advanced AI computing technology from TSMC, Intel, Nvidia, and SuperMicro, offering superior performance for the complex, confidential compute, machine learning workloads required by the Cocoon AI Network. AlphaTON Capital’s deployment adds critical computing capacity to Telegram’s decentralized AI infrastructure, supporting the network’s mission to provide secure, distributed AI services to over one billion users.

Democratizing AI Infrastructure Through the #OwnYourNode Program

The #OwnYourNode program offers flexible ownership options designed to accommodate participants at every level:

  • Fractionalized GPU Ownership: Enabling entry-level participation with fractional shares of GPU computing power
  • Whole GPU Ownership: Full ownership of individual GPU nodes for those seeking complete control
  • Mini Cluster Solutions: Multi-GPU packages for institutions and serious participants seeking scaled deployment

All node owners will benefit from the revenue generated by their computing resources as they support the Cocoon AI Network’s operations, creating a direct economic incentive aligned with network growth.

Josh Hambrook, CEO of Atlantian Cybernetics Development Cluster (AC|DC), AlphaTON’s partner on this decentralized compute initiative, said, “At pivotal moments in history, societies redefine the foundations on which their future will stand. The #OwnYourNode initiative reflects such a moment. For decades, the core infrastructure that shapes our digital lives has been concentrated in ways that limit broad participation and collective benefit. By opening direct ownership of advanced compute to individuals and institutions, we are widening the circle of agency and enabling people to take part in the intelligence economy rather than simply observe it.

Our strategic partnership with AlphaTON is not only a technical achievement. It is the beginning of a new civic architecture for AI. When citizens, entrepreneurs, educators, researchers, and nations can hold real stake in the systems that analyze their world, the relationship between society and technology begins to change. Power becomes more distributed. Value becomes more accessible. Innovation becomes more accountable to the communities it touches.

The activation of H200 GPUs on the Cocoon network is a signal that participation in AI will no longer be reserved for a select few. Humanity deserves infrastructure that includes rather than excludes, and systems that strengthen resilience rather than concentrate vulnerability. #OwnYourNode is designed to advance this shift by transforming compute from a distant utility into a shared civic asset. It is a step toward a future in which the benefits of AI are co-created by the people the technology is intended to serve.”

How to Participate

Individuals and institutions interested in being among the first to own nodes on Telegram’s Cocoon AI network can sign up for priority access at:  https://alphatoncapital.com/ownyournode/




About AlphaTON Capital Corp. (Nasdaq: ATON)





AlphaTON Capital Corp (NASDAQ: ATON) is the world’s leading technology public company scaling the Telegram super app, with an addressable market of 1 billion monthly active users while managing a strategic reserve of digital assets. The Company implements a comprehensive M&A and treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram’s billion-user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company. Led by Chief Executive Officer Brittany Kaiser, Executive Chairman and Chief Investment Officer Enzo Villani, and Chief Business Development Officer Yury Mitin, the Company’s activities span network validation and staking operations, development of Telegram-based applications, and strategic investments in TON-based decentralized finance protocols, gaming platforms, and business applications.

AlphaTON Capital Corp is incorporated in the British Virgin Islands and trades on Nasdaq under the ticker symbol “ATON”. AlphaTON Capital, through its legacy business, is also advancing first-in-class therapies targeting known checkpoint resistance pathways to achieve durable treatment responses and improve patients’ quality of life. AlphaTON Capital actively engages in the drug development process and provides strategic counsel to guide the development of novel immunotherapy assets and asset combinations. To learn more, please visit https://alphatoncapital.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or AlphaTON’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the development and adoption of AI technologies, cryptocurrency market volatility, regulatory developments, technical challenges in infrastructure deployment, and general economic conditions. AlphaTON undertakes no obligation to update any forward-looking statements, except as required by law.

Investor Relations:


AlphaTON Capital Corp
[email protected]
(203) 682-8200

Media Inquiries:
Richard Laermer
RLM PR
[email protected]
(212) 741-5106 X 216



Richard Laermer
AlphaTON (at) rlmpr.com

Posted on

Paychex Unveils Intelligent AI Solutions to Revolutionize Workforce Management

Paychex Unveils Intelligent AI Solutions to Revolutionize Workforce Management

Company continues to democratize access to enterprise-grade AI-driven technologies

ROCHESTER, N.Y.–(BUSINESS WIRE)–Paychex, Inc. (Nasdaq: PAYX), an industry-leading human capital management (HCM) company, announced today a suite of AI-driven innovations to transform the HCM experience, evolving from user-directed to AI-powered with expertise infused at every touch point. Through AI-driven solutions that anticipate needs, automate tasks, and deliver precise, actionable insights, Paychex is simplifying complex HR processes, improving business outcomes, and driving greater efficiency for clients — while fueling the company’s growth.

Paychex recently deployed agentic AI solutions for payroll automation, created an innovative patent-pending system for extracting AI insights from unstructured data, and launched GenAI platforms for personalized recommendations. These recent advancements build on prior innovations, such as AI Assistants leveraging the company’s robust knowledge base that have answered millions of client inquiries via a simple, conversational chat interface. This marks the next phase in Paychex’s vision to reinvent the HCM experience across its three purpose-built platforms – Paychex Flex®, Paycor®, and SurePayroll – as AI-first, transforming AI from a tool to a teammate and ushering in a new era of AI-enabled workforce management.

“We are accelerating innovation across our platforms to democratize AI with a goal of making enterprise-grade AI technology accessible to all businesses,” said John Gibson, president and CEO of Paychex. “Our goal is to empower them to achieve business outcomes faster and compete in today’s dynamic workforce landscape. Success in AI hinges on the quality and scale of data, and with one of the industry’s richest datasets, we are uniquely positioned to drive superior AI performance and insights. While many companies deploy AI, few achieve measurable results. Paychex has a history of achieving clear, measurable business outcomes that drive revenue, efficiency, and client satisfaction.”

Key AI-driven innovations include:

  • Agentic AI Service Capabilities: Paychex successfully deployed agentic AI technology to process thousands of client payrolls via voice and email channels, achieving near 100% accuracy. This innovation accelerates resolution times and enables service teams to shift from transactional tasks to higher-value strategic advisory support.
  • AI Data Transformation Patent: Paychex’s patent-pending AI-powered knowledge mesh system breaks down silos of unstructured data (such as phone calls and emails) across traditional systems and organizes it into a connected, searchable network that generates actionable workforce management intelligence. This advanced technology enables Paychex to deliver personalized, data-driven insights that enhance decision-making, efficiency, and the overall client experience.
  • GenAI Employment Law Platform: Paychex recently launched a GenAI-powered employment law and compliance platform that empowers Paychex HR experts and clients to efficiently navigate thousands of complex employment laws, create compliant documents, and stay informed about regulatory updates.
  • GenAI Sales & Service Platform: A unified agent navigates various systems to aggregate insights and deliver personalized, relevant support for sales and service teams to enhance client interactions. Sales teams receive instant answers and tailored suggestions on sales scripts, objection handling, and policies through our AI-powered chat platform. Meanwhile, service teams are seeing early success with similar capabilities to enhance customer support, such as assessing past client interactions to anticipate their needs with proactive support.

To learn more about how Paychex leverages AI as a force multiplier—automating routine tasks, delivering personalized experiences, and uncovering actionable insights at scale —visit go.paychex.com/ai.

About Paychex

Paychex, Inc. (Nasdaq: PAYX) is the digitally driven HR leader that is reimagining how companies address the needs of today’s workforce with the most comprehensive, flexible, and innovative HCM solutions for organizations of all sizes. Offering a full spectrum of HR advisory and employee solutions, Paychex pays 1 out of every 11 American private sector workers and is raising the bar in HCM for approximately 800,000 customers in the U.S. and Europe. Every member of the Paychex team is committed to fulfilling the company’s purpose of helping businesses succeed. Visit paychex.com to learn more.

Media Contact

Tracy Volkmann

Manager, Public Relations

Paychex, Inc.

(585) 387-6705

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Payments Professional Services Technology Artificial Intelligence Human Resources

MEDIA:

Logo
Logo
Posted on

INVESTOR REMINDER: Berger Montague Notifies James Hardie Industries PLC (NYSE: JHX) Investors of a Class Action Lawsuit and Deadline

PR Newswire


PHILADELPHIA
, Dec. 8, 2025 /PRNewswire/ — National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against James Hardie Industries plc (NYSE: JHX) (“James Hardie” or the “Company”) on behalf of investors who purchased James Hardie common stock or American Depositary Shares during the period of May 20, 2025 through August 18, 2025(the “Class Period”).


Investor Deadline:

Investors who purchased James Hardie securities during the Class Period may, no later than December 23, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,


CLICK HERE

.

James Hardie, headquartered in Dublin, Ireland, is a global building materials company and the world’s largest manufacturer of fiber cement products.

The Complaint alleges that during the Class Period, James Hardie misled investors about the strength of its core North America Fiber Cement segment. The Company is alleged to have represented that demand remained strong and inventory levels were normal, despite knowing by April and early May 2025 that distributors were destocking inventory.

On August 19, 2025, James Hardie revealed a 12% decline in the segment, attributing it to the “normalization of channel inventories” while warning of continued weakness. Following this disclosure, the Company’s stock price fell more than 34%, causing significant investor losses.


If you are a James Hardie investor and would like to learn more about this action,




CLICK HERE


 or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

About Berger Montague

Berger Montague is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:

Andrew Abramowitz

Senior Counsel

Berger Montague

(215) 875-3015
[email protected]

Caitlin Adorni

Director of Portfolio & Institutional Client Monitoring Services

Berger Montague

(267) 764-4865
[email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-reminder-berger-montague-notifies-james-hardie-industries-plc-nyse-jhx-investors-of-a-class-action-lawsuit-and-deadline-302635512.html

SOURCE Berger Montague

Posted on

Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India

PR Newswire

Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing


SALT LAKE CITY
, Dec. 9, 2025 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. (“CoSara”), the joint venture (“JV”) between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will participate and host a booth at VIROCON 2025, taking place December 8-10 at the Conrad Hotel in Pune, Maharashtra, India.

CoSara is currently supporting the second phase of the Company’s preclinical studies for the Co-Dx PCR MTB (tuberculosis) test and Co-Dx PCR HPV multiplex test on the Co-Dx PCR point-of-care (PoC) platform*. Phase I of the MTB test studies included 354 clinical specimens from sputum and tongue swabs to provide early sensitivity and specificity assessments, while Phase II has evaluated 211 sputum specimens in a comparison evaluation against other tests to establish concordance for Mycobacterium tuberculosis detection. The studies are being conducted in preparation of advancement to clinical performance testing, required by Indian regulatory authorities prior to submission.

Phase I of the preclinical studies for the 8-type HPV multiplex test, designed to identify the presence of eight different human papillomavirus genotypes, evaluated 286 clinical specimens to validate and optimize the Co-Primers® test chemistry for HPV. Three of the eight genotypes are classified as high-risk for cancer, and in Phase II, 53 specimens have been analyzed to date to facilitate the differential detection of the three high-risk HPV genotypes as the application algorithm continues to be trained, refined and optimized.

The Company believes that data gathered thus far in the preclinical studies for both tests support advancement to clinical performance testing, as part of the pathway to regulatory submissions.

Attendees interested in learning more about CoSara products, including the TB and HPV tests on the Company’s upcoming Co-Dx PCR platform, are encouraged to stop by at VIROCON 2025. CoSara will be available for meetings and interactions at CoSara’s booth.

VIROCON 2025 is organized by the India Council of Medical Research – National Institute of Virology (“ICMR-NIV”), with this year’s theme being “Changing Landscape in Human, Animal, and Plant Viruses: Bridging Basic Science, Innovations and Public Health.” The conference is expected to provide a platform for productive scientific deliberations and collaborations aimed at developing solutions to contain the viral epidemics that threaten human, animal, plant, aquatic and environmental health.


*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Forward-looking statements include statements made with respect to our Co-Dx PCR platform and tests, including statements about potential or future clinical performance studies, regulatory submissions, product performance, market opportunities, or commercialization efforts related to the Co-Dx PCR platform and associated tests. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 27, 2025, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india-302635378.html

SOURCE Co-Diagnostics

Posted on

Schwab Trading Activity Index™: STAX Score Continues Upswing for Sixth Consecutive Month

Schwab Trading Activity Index™: STAX Score Continues Upswing for Sixth Consecutive Month

Schwab clients were net buyers of equities in November, continuing three-month streak of outpacing the S&P 500® index (SPX)

WESTLAKE, Texas–(BUSINESS WIRE)–
The Schwab Trading Activity Index™ (STAX) increased to 48.75 in November, up from its score of 48.12 in October. The only index of its kind, the STAX is a proprietary, behavior-based index that analyzes retail investor stock positions and trading activity from Schwab’s millions of client accounts to illuminate what investors were actually doing and how they were positioned in the markets each month.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208229419/en/

“’Buy the dip and sell the rip’ continues to be something of a rallying cry this year for retail investors at Schwab, who took opportunities in November to sell into strength and pick up mega-cap stocks that experienced pullbacks,” said Joe Mazzola, Head Trading and Derivatives Strategist at Charles Schwab. “The degree to which clients net-bought in November was significant – in the top-third of all STAX periods to date.”

The STAX outpaced the S&P 500® index (SPX) for the third-straight month though notably the S&P 500 rose by only about 0.1%. The score hit its highest mark since February of this year, but net-buying peaked around mid-month and fell the rest of the way, posting its softest reading in the final week of November when the S&P 500 index rose nearly 4%. That downward trend for STAX in late November ended a four-month streak in which the highest STAX weekly score occurred in the final week.

At the sector level, only two of the eleven saw net-buying from Schwab clients during November: Information Technology and Consumer Discretionary. The biggest net-sell sectors were Communication Services, Health Care, and Energy, bucking Wall Street trends.

The government shutdown that began in October and continued into November meant investors had to rely on private sector labor market data, all of which showed slowing economic and consumer sentiment. Major indexes spent much of November losing ground amid weakness in Magnificent Seven names and cryptocurrencies, hurt partly by falling hopes for a December rate cut by the Federal Reserve. However, the market got a significant boost toward the end of the month when New York Federal Reserve President John Williams signaled a preference for a rate cut in December, bringing the likelihood of a cut from a low of 40% into the high-80s according to the CME FedWatch Tool.

As in October, the most aggressively positioned investors tracked by Schwab during November again belonged to Generation X, born between 1965 and 1980. Among the least aggressive was Generation Z, born between 1997 and 2012.

Popular names bought by Schwab clients during the period included:

  • NVIDIA Corp. (NVDA)
  • Palantir Technologies Inc. (PLTR)
  • Meta Platforms Inc. (META)
  • Amazon.com Inc. (AMZN)
  • Tesla Inc. (TSLA)

Names net sold by Schwab clients during the period included:

  • Apple Inc. (AAPL)
  • Broadcom Inc. (AVGO)
  • Eli Lilly and Co. (LLY)
  • Intel Corp. (INTC)
  • Rivian Automotive Inc. (RIVN)

About the STAX

The STAX value is calculated based on a complex proprietary formula. Each month, Schwab pulls a sample from its client base of millions of funded accounts, which includes accounts that completed a trade in the past month. The holdings and positions of this statistically significant sample are evaluated to calculate individual scores, and the median of those scores represents the monthly STAX.

For more information on the Schwab Trading Activity Index, please visit www.schwab.com/investment-research/stax. Additionally, Schwab clients can chart the STAX using the symbol $STAX in either the thinkorswim® or thinkorswim Mobile platforms.

Investing involves risk, including loss of principal. Past performance is no guarantee of future results.

Content intended for educational/informational purposes only. Not investment advice, or a recommendation of any security, strategy, or account type.

Historical data should not be used alone when making investment decisions. Please consult other sources of information and consider your individual financial position and goals before making an independent investment decision.

The STAX is not a tradable index. The STAX should not be used as an indicator or predictor of future client trading volume or financial performance for Schwab.

About Charles Schwab

At Charles Schwab, we believe in the power of investing to help individuals create a better tomorrow. We have a history of challenging the status quo in our industry, innovating in ways that benefit investors and the advisors and employers who serve them, and championing our clients’ goals with passion and integrity.

More information is available at aboutschwab.com. Follow us on X, Facebook, YouTube, and LinkedIn.

1225-H6NX

At the Company

Margaret Farrell

Director, Corporate Communications

(203) 434-2240

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo
Logo
Posted on

MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire


LOS ANGELES
, Dec. 8, 2025 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with losses related to MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MOONLAKE (MLTX) CLICK HERE
BEFORE DECEMBER 15, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

 What Is The Lawsuit About?
The complaint filed alleges that, between March 10, 2024 and September 29, 2025, Defendants failed to disclose to investors that: (1) that SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) that SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content:https://www.prnewswire.com/news-releases/moonlake-immunotherapeutics-mltx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302633950.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

Posted on

StubHub Holdings, Inc. (STUB) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire


LOS ANGELES
, Dec. 8, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against StubHub Holdings, Inc. (“StubHub” or the “Company”) (NYSE: STUB).

IF YOU SUFFERED A LOSS ON YOUR STUBHUB INVESTMENTS, CLICK HERE BEFORE JANUARY 23, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s September 2025 initial public offering, Defendants failed to disclose to investors that: (1) the Company was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on free cash flow, including trailing 12 months (“TTM”) free cash flow; (3) as a result, the Company’s free cash flow reports were materially misleading; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 

Glancy Prongay & Murray LLP,  
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Cision View original content:https://www.prnewswire.com/news-releases/stubhub-holdings-inc-stub-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302633868.html

SOURCE Glancy Prongay & Murray LLP

Posted on

CarMax, Inc. (KMX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire


LOS ANGELES
, Dec. 8, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX).

IF YOU SUFFERED A LOSS ON YOUR CARMAX INVESTMENTS, CLICK HERE
BEFORE JANUARY 2, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, between June 20, 2025 and November 5, 2025, Defendants failed to disclose to investors that: (1) Defendants recklessly overstated CarMax’s growth prospects when, in reality, its earlier growth in the 2026 fiscal year was a temporary benefit from customers buying cars due to speculation regarding tariffs; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 

Glancy Prongay & Murray LLP,  
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/carmax-inc-kmx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302633871.html

SOURCE Glancy Prongay & Murray LLP

Posted on

Avantor, Inc. (AVTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire


LOS ANGELES
, Dec. 8, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR).

IF YOU SUFFERED A LOSS ON YOUR AVANTOR INVESTMENTS, CLICK HERE
BEFORE DECEMBER 29, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, between March 5, 2024 and October 28, 2025, Defendants failed to disclose to investors that: (1) Avantor’s competitive positioning was weaker than Defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 

Glancy Prongay & Murray LLP,  
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-inc-avtr-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302633892.html

SOURCE Glancy Prongay & Murray LLP

Posted on

Surgery Partners and Baylor Scott & White Health Form Joint Venture to Expand Access to Quality Care

The Physicians Centre Hospital in Bryan to become a Baylor Scott & White facility, as health system grows to keep up with population increase in the Brazos Valley

BRENTWOOD, Tenn., and BRYAN/COLLEGE STATION, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) announces a new partnership with Baylor Scott & White Health, the largest not-for-profit health system in Texas, to jointly own with physicians the 16-bed hospital in Bryan known as The Physicians Centre Hospital*. Patients will be able to continue care with their current provider at the location. The hospital will operate under the Baylor Scott & White name in the future, with Surgery Partners continuing to manage daily operations.

The hospital has been recognized for surgical excellence and patient satisfaction. It offers a broad range of surgical options for bariatric, ophthalmologic, oral/maxillofacial, orthopedic, gastroenterological, podiatric, spinal and urologic conditions. The team also provides general, plastic, and reconstructive surgery, as well as sports medicine, pain management and radiology services.

“This marks a significant step forward in expanding access to quality patient care in the Bryan College Station community,” said Mike Sanborn, chief growth officer, Baylor Scott & White. “This joint venture partnership reflects our ongoing dedication to customer-centered care and strategic growth in the communities we serve.”

This facility will complement the surgical care services offered throughout the Baylor Scott & White – College Station Region, for a full continuum of surgical care close to home.

“We are committed to offering our patients access to exceptional care close to where they live and work,” said Jason Jennings, president, Baylor Scott & White – College Station Region. “This partnership allows us to further enhance our services and deliver a seamless experience for our community as it continues to grow.”

“We are excited to add Baylor Scott & White to our partnership at The Physicians Centre Hospital,” said Jennifer Baldock, Executive Vice President, Chief Administrative & Development Officer. “The new joint venture integrates our patient-centric hospital with one of the nation’s most respected health systems and provides the opportunity to serve additional patients, attract new physician partners, and broaden our breadth and depth of services.”

About Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.

About Baylor Scott & White Health

As the largest not-for-profit health system in the state of Texas, Baylor Scott & White is empowering customers to live well by reimagining traditional healthcare — creating more convenient, personalized and informed experiences. It serves more than three million customers through 53 hospitals, including flagship academic medical centers in Dallas, Fort Worth and Temple; the Baylor Scott & White Research Institute; 1,300+ access points; 59,000+ team members; and its leading digital platform — MyBSWHealth. The system’s award-winning employer solutions include Baylor Scott & White Health Plan, Baylor Scott & White Quality Alliance and Levanto — a company offering digitally enabled health products. Founded as a Christian ministry of healing more than a century ago, Baylor Scott & White’s mission is to promote the health and well-being of all individuals, families and communities.

For more information, visit: BSWHealth.com

*Joint Ownership with Physicians / Notice Regarding Physician Ownership: These are hospitals in which physicians have an ownership or investment interest. The list of physician owners or investors is available to you upon request. Physicians provide clinical services as members of the medical staff at one of Baylor Scott & White Health’s subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers nor Baylor Scott & White Health.

Contacts:

Surgery Partners Investor Relations
(615) 234-8940
[email protected]

Baylor Scott & White Media Contact: Christy Millweard
(512) 366-7877
[email protected]